Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia (CLL).

PURPOSE: CD38 has emerged as a high-impact therapeutic target in multiple myeloma, with the approval of daratumumab (anti-CD38 monoclonal antibody). The clinical importance of CD38 in chronic lymphocytic leukemia (CLL) patients has been known for over two decades, though it’s relevance as a therapeu...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Manna, Alak, Aulakh, Sonikpreet, Jani, Prachi, Ahmed, Salman, Akhtar, Sharoon, Coignet, Marie, Heckman, Michael G., Meghji, Zahara, Bhatia, Kirtipal, Sharma, Aarushi, Sher, Taimur, Alegria, Victoria, Malavasi, Fabio, Chini, Eduardo N., Chanan-Khan, Asher, Ailawadhi, Sikander, Paulus, Aneel
Format: Artigo
Jezik:Inglês
Izdano: 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6744942/
https://ncbi.nlm.nih.gov/pubmed/30940652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3412
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items